(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) slid by a staggering 34.9% in 30 days from $2.55 to $1.66 at 13:06 EST on Friday, after two successive sessions in a row of losses. NASDAQ is sliding 2.22% to $10,821.30, after three successive sessions in a row of losses.
Inovio Pharmaceuticals’s last close was $1.77, 80.07% below its 52-week high of $8.88.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These drugs are used to protect and treat people against diseases such as cancer, human papillomavirus, and other infectious diseases. The DNA medicines platform utilizes precisely-designed SynCon to identify and optimize DNA sequences of target antigens. CELLECTRA smart device technology facilitates the delivery of DNA plasmids. It plans clinical trials of DNA medicines to treat HPV-associated diseases, such as cervical, vulvar and anal dysplasia. ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, (DARPA), Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency, Department of Defense (DoD), HIV Vaccines Trial Network, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, Thero Fisher Scientific, Thermo Fisher Military Institute of Research, The Wistar Institute of Research, University of Research, Walter Reed Army Institute of Research, University of Research, University of Research, University of Research, University of Research, University of Research, Thero Fisher Scientific, Thermo Fisher Research, Thermo Fisher to support thero Fisher and Thero Fisher Scientific, Thermo Fisher Research, Thermo Fisher Research, University of Research, Thermo Fisher To support the investigational DNA vaccine, INO-4800, for COVID-19, Richter-Helm BioLogics GmbH & Co. KG has been entered into an agreement. The partnership also includes International Vaccine Institute (Seoul National University Hospital) and Regeneron Pharmaceuticals. Plymouth Meeting is the headquarters of this company, which was established in 1979.
Today’s last reported volume for Inovio Pharmaceuticals is 1615943 which is 72.65% below its average volume of 5908728.
Inovio Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth declined by 46.4%, now sitting on 1.6M for the twelve trailing months.
Inovio Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.48%, a negative 1.36%, and a positive 5.57%, respectively.
Inovio Pharmaceuticals’s highest amplitude of average volatility was 5.10% (last week), 4.47% (last month), and 5.57% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Inovio Pharmaceuticals’s stock is considered to be overbought (>=80).
Inovio Pharmaceuticals’s Stock Yearly Top and Bottom Value
Inovio Pharmaceuticals’s stock is valued at $1.66 at 13:06 EST, way under its 52-week high of $8.88 and way higher than its 52-week low of $1.38.
Inovio Pharmaceuticals’s Moving Average
Inovio Pharmaceuticals’s value is way under its 50-day moving average of $2.19 and way below its 200-day moving average of $3.38.
More news about Inovio Pharmaceuticals (INO).